Dermata to Present at the H.C. Wainwright BioConnect Conference

Rhea-AI Summary

Dermata Therapeutics (NASDAQ:DRMA), a clinical-stage biotechnology company, announced that Gerry Proehl, its Chairman, President, and CEO, will present at the H.C. Wainwright BioConnect Conference from January 10-13, 2022. The presentation will be available on-demand starting January 10 at 7:00 a.m. ET. Dermata focuses on treating skin conditions with its lead product candidate, DMT310, aimed at acne, psoriasis, and rosacea. The company’s second candidate, DMT410, is designed for topical administration of botulinum toxin. A replay will be accessible on Dermata's website for 90 days.

SAN DIEGO, CA / ACCESSWIRE / January 5, 2022 / Dermata Therapeutics, Inc. (NASDAQ:DRMA) ("Dermata" or the "Company"), a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, today announced that Gerry Proehl, Dermata's Chairman of the Board, President, and Chief Executive Officer, will present a company overview at the H.C. Wainwright BioConnect Virtual Conference being held January 10-13, 2022. The on-demand presentation will be available starting at 7:00 a.m. ET on Monday, January 10, 2022 and can be accessed by clicking the following link: https://journey.ct.events/view/c8870e93-b827-4340-a020-11c53c2b4f59.

A replay of the webcast will be available under the ‘News and Events' section of the Investor Relations tab of the company's website at: www.dermatarx.com. The webcast will be archived for approximately 90 days.

About Dermata

Dermata Therapeutics, Inc. is a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions. The Company's lead product candidate, DMT310, is the first product candidate being developed from its Spongilla technology platform. DMT310 is a once-weekly topical product candidate derived from a naturally sourced freshwater sponge with multiple unique mechanisms of action. DMT310 is in clinical development for the topical treatment of acne, psoriasis, and rosacea. Dermata's second product candidate, DMT410, uses its Spongilla technology as a new method for topical intradermal delivery of botulinum toxin for the treatment of multiple aesthetic and medical skin conditions. Dermata is headquartered in San Diego, California. For more information, please visit http://www.dermatarx.com/.

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are based on the Company's current beliefs and expectations and new risks may emerge from time to time. Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions, and other factors including, but are not limited to, statements related to: the potential development and commercialization of product candidates; the ability of the Company's product candidates to achieve applicable endpoints in clinical trials; whether the results of the Company's product candidates will lead to future product development; and whether the Company will have the ability to obtain adequate funding for future development of its product candidates. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in drug development, approval and commercialization, and the fact that past results of clinical trials may not be indicative of future trial results. For a discussion of these and other factors, please refer to Dermata's filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and Dermata undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof, except as required by law.

Investors:
Sean Proehl
Senior Director, Legal and Business Development
info@dermatarx.com

SOURCE: Dermata Therapeutics

View source version on accesswire.com:
https://www.accesswire.com/681007/Dermata-to-Present-at-the-HC-Wainwright-BioConnect-Conference

FAQ

What is Dermata Therapeutics' lead product candidate, DMT310?

DMT310 is a topical product candidate developed from Dermata's Spongilla technology platform, targeting acne, psoriasis, and rosacea.

When will Dermata Therapeutics present at the H.C. Wainwright BioConnect Conference?

Dermata Therapeutics will present at the conference from January 10-13, 2022, with the on-demand presentation available starting January 10 at 7:00 a.m. ET.

How can I access the Dermata Therapeutics presentation?

The presentation can be accessed via a link provided in their press release, as well as through the Investor Relations section of Dermata's website.

Where can I find the replay of Dermata's presentation after the conference?

The replay of the presentation will be available for about 90 days under the 'News and Events' section of Dermata's Investor Relations tab on their website.

What is the focus of Dermata Therapeutics as a biotechnology company?

Dermata Therapeutics focuses on developing treatments for medical and aesthetic skin conditions.